Physician profile
Nathan Warder
NPI 1093349052
$18,747.28
in general payments reported to CMS, 2019-2025
32 companies · $4,074 in 2025
The $4,074 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,523 · 2022: $3,575 · 2023: $4,698 · 2024: $3,878 · 2025: $4,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,276.42 |
| Education | $372.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $5,146.26 | 2021-2025 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $1,927.90 | 2021-2025 | |
| Janssen Biotech, INC. | $1,850.11 | 2021-2025 | Tremfya |
| Ucb, INC. | $1,664.23 | 2021-2025 | Cimzia, Bimzelx |
| Lilly USA, LLC | $1,290.79 | 2021-2025 | Taltz, Zepbound |
| Novartis Pharmaceuticals Corporation | $1,188.39 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $883.12 | 2021-2025 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $775.34 | 2021-2025 | Acthar |
| Horizon Therapeutics Plc | $574.10 | 2021-2023 | Krystexxa |
| Janssen Scientific Affairs, LLC | $572.55 | 2022-2025 | Tremfya |
| Glaxosmithkline, LLC. | $541.99 | 2021-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $435.64 | 2021-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $397.28 | 2021-2024 | Ofev, Cyltezo |
| Pfizer INC. | $345.36 | 2021-2025 | |
| Radius Health, INC. | $284.27 | 2022-2025 | Tymlos |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $172.69 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $139.91 | 2021-2025 | Lupkynis |
| Fresenius Kabi USA, LLC | $107.31 | 2023-2025 | Idacio, Tyenne |
| Alexion Pharmaceuticals, INC. | $71.28 | 2025 | Strensiq |
| Almatica Pharma LLC | $55.33 | 2024-2025 | Teriparatide |
| Fidia Pharma USA INC. | $50.87 | 2021-2023 | Triluron, Hymovis |
| Sandoz INC. | $35.64 | 2023 | Hyrimoz |
| Organon LLC | $31.33 | 2024 | |
| Pacira Therapeutics, INC. | $30.61 | 2021 | |
| Alvogen INC | $30.53 | 2022 | |
| Mylan Institutional INC. | $24.02 | 2023 | Hulio |
| Sobi, INC | $22.61 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $22.48 | 2023 | Zilretta, Iovera |
| Ultragenyx Pharmaceutical INC. | $20.84 | 2024 | Crysvita |
| Cumberland Pharmaceuticals, INC. | $19.41 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $17.94 | 2024 | Simlandi |
| Ani Pharmaceuticals, INC. | $17.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Warder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.